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Thrombospondin and tumor necrosis factor
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Progress in two main projects in my laboratory are discussed:
(1) the study of the extracellular matrix/cell surface molecule
thrombospondin (TSP); and (ii) the characterization of primary
or immediate early response genes induced by tumor necrosis
factor-a (TNF).
Thrombospondin
Thrombospondin (TSP) is a platelet and cell derived homo-
trimeric glycoprotein of molecular weight 450,000 daltons. TSP
is released from platelet a-granules upon activation and plays
an essential role in the secretion dependent phase of platelet
aggregation. In addition, TSP is synthesized and secreted by a
variety of cells in culture and is a component of the extracellular
matrix. TSP binds a variety of ligands including heparin,
collagen, fibronectin, fibrinogen, plasminogen and plasminogen
activator [reviewed in 1]. These interactions are mediated by
various protease resistant regions or domains that compose the
TSP molecule. One such domain is the amino terminal heparin
binding domain that contains a high affinity site for heparin.
This domain had been identified by subjecting proteolytic
fragments of TSP to heparin Sepharose chromatography. The
isolated heparin binding domain is a monomeric peptide of
25,000 dalton molecular weight. Since the N-terminal amino
acid sequence of the heparin binding domain is identical to that
of the intact TSP molecule, the heparin binding domain must
reside at the very N-terminus of TSP [2]. The amino acid
sequence of the heparin binding domain as predicted from the
nucleotide sequence of TSP cDNA reveals it to be hydrophobic
in character and to contain two clusters of basic amino acids
that contribute to the binding of anionic heparin [3]. A number
of findings suggest that the heparin binding domain is of major
physiological relevance. Heparin, presumably by binding to the
heparin binding domain, inhibits the incorporation of radiola-
beled TSP into isolated cell matrices. In addition, by the same
mechanism heparin inhibits the incorporation of newly synthe-
sized TSP onto the cell surface of aortic smooth muscle cells.
Recent evidence suggests that the cell surface receptor for TSP
is a heparan sulfate proteoglycan and heparin by competing for
the binding of TSP to this receptor is capable of inhibiting cell
surface association [4, 5]. A variety of evidence which is
outlined below suggests that TSP plays an important role in the
growth response of aortic smooth muscle cells.
When quiescent aortic smooth muscle cells are treated with a
mitogen, platelet derived growth factor (PDGF), TSP levels are
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induced rapidly, (that is, within 15 mm) and in a dose dependent
manner. Importantly, the induction of TSP message parallels
PDGF mediated mitogenesis. Further, in the presence of the
protein synthesis inhibitor cycloheximide, PDGF superinduces
the TSP transcript [61. As a whole, these data suggest that
mRNA levels for TSP are regulated by PDGF in a manner
similar to that of c-myc, c-fos and other growth regulatory gene
products. This rapid induction of TSP message together with its
superinducibility in the combined presence of PDGF and cy-
cloheximide suggests that TSP may be a member of the com-
petence gene family that mediates the mitogenic response of
cells to PDGF [6]. Once synthesized and secreted, TSP binds to
the smooth muscle cell surface and extracellular matrix where it
plays a growth facilitative role. For example, TSP and epider-
mal growth factor (EGF) act synergistically to stimulate DNA
synthesis by smooth muscle cells. The 30-hour nuclear labeling
index increases from a mean of 7% in quiescent cells to 20% for
EGF treated smooth muscle cells. However, TSP and EGF act
synergistically, stimulating DNA synthesis to give a labeling
index of 47%. This facilitative effect of TSP on EGF mediated
smooth muscle cell proliferation is inhibited by heparin. Hep-
arm, a known inhibitor of aortic smooth muscle cell growth and
migration, inhibits the incorporation of TSP into the aortic
smooth muscle cell surface/matrix compartment. This is a dose
dependent phenomenon with a maximal effect seen at a heparin
concentration of 1 g/ml. Thus, it is conceivable that the
antiproliferative effect of heparin is mediated through its inhi-
bition of incorporation of TSP into the extracellular matrix.
Support for such a hypothesis comes from studies showing that
either polyclonal or monoclonal antibodies against TSP inhibit
aortic smooth muscle cell proliferation and migration [7]. Aortic
smooth muscle cells treated with an anti-TSP monoclonal
antibody results in a greater than 60% reduction in cell number
by the eighth day. These cells are morphologically identical to
control cells and when analyzed by flow cytofluorometry are
found to be arrested in the G 1 phase of the cell cycle [7]. The
anti-TSP monoclonal antibody-like heparin abolishes cell sur-
face expression of TSP as demonstrated by immunofluores-
cence and metabolic labeling experiments [7]. These studies
suggest that cell surface associated TSP is functionally essential
for smooth cell proliferation and that this requirement is located
in the 01 phase of the cell cycle. Agents that perturb the
interaction of TSP with the smooth muscle cell surface such as
heparin or anti-TSP antibodies inhibit smooth muscle cell
proliferation [71. Recently, it has been shown that TSP deposi-
tion occurs in vivo following rat carotid artery injury. One hour
following balloon catheter injury, prominent cell associated
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TSP immunostaining is evident in the media. In this rat model,
intimal proliferation is evident five days after balloon injury.
TSP staining is especially profound in the neointima and media
compared to non-operated controls. This in vivo data supports
the hypothesis that TSP expression is an early response to
injury and is localized predominantly to areas of smooth muscle
cell proliferation.
The mechanism by which TSP promotes cell migration is likely
related to its ability to act as a focus for protease generation. TSP
has previously been shown in in vitro assays to bind both
plasminogen and plasminogen activator resulting in a 40-fold
increase in the efficiency of plasmin generation. Furthermore, the
plasmin generated remains bound to TSP and is protected from
inactivation by plasmin inhibitors [8]. More recently, specific
complex formation of TSP with urokinase has been demonstrated
and these complexes as well are protected from inhibition by
plasminogen activator inhibitor. These workers also demonstrated
co-distribution of TSP and urokinase in normal and malignant
breast tissue. Thus, TSP may play an important role in the
extracellular matrix via its ability to facilitate matrix degradation
and remodeling that accompanies the proliferation and migration
of mesenchymal and tumor cells [9]. We have explored further the
potential role of TSP in tumor cell invasiveness by utilizing a
genetic approach. We transfected a highly invasive squamous
carcinoma cell line that produced large amounts of TSP with a
TSP cDNA antisense expression vector. Three unique transfected
clones were characterized, all of which expressed the transfected
antisense transcript to varying degrees as verified by a ribonucle-
ase protection assay. Most importantly, these clones showed
corresponding reduction in TSP protein and interestingly a corre-
sponding decrease in invasive potential, further emphasizing a role
for TSP in cell migration [10]. Given the facilitative effects of TSP
on cell growth and migration we have embarked upon examining
what role TSP may play in embryogenesis. As assessed by
immunocytochemistry TSP is densely deposited in the developing
nervous system in regions of cell migration [11, 12]. For example,
during histogenesis of the cerebellar cortex, TSP is found depos-
ited around granule cells as they migrate through the molecular
layer. When anti-TSP antibodies are added to explant cultures of
cerebellar cortex during active granule cell migration, a dose-
dependent inhibition of migration is observed. In control cultures,
granule cells migrate into the internal granule cell layer, while
granule cells exposed to anti-TSP antibodies are arrested within
the external granule cell layer. These results suggest that TSP
plays an important role in the histogenesis of the cerebellar cortex
by influencing cell migratory events Ill].
Until recently, all the myriad activities associated with TSP
ranging from platelet aggregation to neurite outgrowth have
been assigned to a single molecule with little evidence for
alternate forms generated either by alternative splicing or as
members of a gene family. However, the existence of a gene
family has received strong support from our recent finding of a
second expressed TSP gene whose gene product has been
designated TSP2 [13].
Comparison of TSPI and TSP2 amino acid sequences reveals
a gradient of sequence conservation, with the amino terminus
which encodes the heparin binding domain being most distinct
and the carboxy terminus most similar [13]. Differences in the
heparin binding domain may cause altered affinities for cell
surface and matrix proteoglycans with resultant alteration in the
distribution of the two TSPs. The discovery of a second TSP
raises a number of questions including: (i) is its synthesis
regulated by growth factors; (ii) is it trimeric and if so, does it
form homo or hetero trimers; (iii) does it mediate cell attach-
ment, platelet aggregation, or neurite outgrowth; (iv) what is the
nature of the cell surface receptor(s) which binds it and; (v) are
there more than just two TSPs?
Tumor necrosis factor
Tumor necrosis factor-w (TNF) is a cytokine that appears to
have a key role in orchestrating the inflammatory response. TNF,
by affecting many target cell types, is capable of inducing a wide
spectrum of pro-inflammatory activities and has been implicated
in mediating a variety of disease states [reviewed in 14]. An
important target cell type is the vascular endothelium. Its strategic
location at the interface of the bloodstream and the tissues makes
it of particular interest in inflammatory processes. Far from being
a passive target in inflammation as had been previously assumed,
it is now known to be an active participant in processes relevant to
inflammation, including those processes induced by TNF and
other cytokines. For example, TNF causes an orchestrated
change in the endothelial coagulation phenotype from anti- to
pro-coagulant. It induces the expression of a tissue factor-like
molecule and a plasminogen activator inhibitor, while decreasing
expression of plasminogen activator and suppressing the protein C
pathway. TNF also induces or increases the expression of adhe-
sive molecules such as endothelial-leukocyte adhesion molecule-l
and intercellular adhesion molecule-l on the endothelial surface,
events which promote interaction of circulating leukocytes with
the endothelium and that can be expected to be pro-inflammatory.
The complex and pleiotropic action of TNF on endothelial cells
suggests that this cytokine may ultimately evoke the expression of
a wide variety of cellular genes. Is seems likely that such genes
may be members of two broad classes. The first class consists of
genes which do not depend on cellular protein syntheses. As such,
these would be akin to the "primary response" or "immediate
early" genes induced in quiescent cells by the addition of growth
factors [15]. The second class of genes requires protein synthesis
for its expression. Since the former class of genes represents the
initial cellular response to TNF, its characterization might be
expected to provide valuable insights into the mechanism of action
of TNF. Indeed, the characterization of serum inducible primary
response genes has led to a better understanding of the mechanism
by which growth factors exert their mitogenic effect. From these
studies it is evident that primary response genes fall into two
categories. The first category encodes transcriptional factors in-
cluding c-fos, c-myc, c-junA, c-junB and zinc finger containing
nuclear proteins [16]. In the second category are paracrine factors
which influence other cells and include the secreted proteins JE
and KC which have significant homology to T cell cytokines [16
and references therein]. It should be noted that both categories of
primary response genes encode cascade initiating proteins that
are capable of influencing a large number of cellular events. It is
obvious, for example, that induction of a transcriptional factor
may activate or repress the transcription of a large number of
genes.
In contrast to growth stimulatory products such as serum,
EGF and PDGF, some cytokines are growth inhibitory. In the
case of TNF, the addition of even small amounts to cultured
endothelial cells in vitro results in a rapid but reversible loss of
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proliferative activity [17]. At present, it is unclear what is the
nature of primary response genes in cells stimulated with
growth inhibitors. Do the primary response genes in such an
instance encode anti-oncogenes, that like the retinoblastoma
gene product serve to block cell cycle progression?
In an attempt to answer these questions, and to begin to
understand the mechanism of TNF action, we undertook the
cloning and characterization of primary response genes induced
by this growth inhibitory cytokine in endothelial cells.
As it was likely, given its pleiotropic biological effects, that
TNF directly and indirectly influenced the transcription of a
very large number of genes, we attempted to limit our analysis
to the cloning of primary response genes. Such genes charac-
teristically undergo rapid and profound induction of transcrip-
tion and are not dependent on intermediary protein synthesis.
In this section we will discuss: a) The strategy used to clone
primary response genes; b) Induction of the nuclear protoon-
cogene c-jun by TNF; and c) TNF mediated induction of other
primary response genes (including three novel ones).
Cloning of TNF-induced primary response genes by
differential hybridization
To restrict the analysis to primary response genes, so that gene
induction was a direct consequence of TNF stimulation, the
induced cDNA library was constructed from endothelial cells
treated with both TNF and cycloheximide (CHX). Using 10 g of
poly (AY RNA from TNF/CHX treated cells, a eDNA library was
constructed in the vector gtll. Ligation and packaging of the
cDNA resulted in a library of 5 x 106 independent recombinants.
Approximately 30,000 plaques of this cDNA library were screened
by differential hybridization with single stranded cDNA probes
complementary to mRNA from both untreated and TNF/CHX
treated cells. Briefly, the differential plaque hybridization was
performed by plating phage at low density in 150 cm2 dishes (2 to
5 plaques/cm2). A duplicate set of nitrocellulose filters was taken
from each dish and hybridized with high specific activity 32P
labelled cDNA probes (2 to 8 x l0 cpm/sg) synthesized by the
reverse transcriptase reaction from poly (A) RNA. Plaques
preferentially hybridizing with cDNA probe from TNF/CHX-
stimulated endothelial cells were rescreened and finally plaque
purified. Differential screening in this manner led to the identifi-
cation of 200 cDNAs that were preferentially expressed in TNF-
stimulated endothelial cells [18]. The differentially hybridizing
cDNAs were screened with probes for genes known to be induced
by TNF. These included plasminogen activator, c-fos, c-myc,
HLA class 1, CSF-l, GM-CSF, intercellular adhesion molecule-l,
and tissue factor [14 and references therein]. Only one hybridizing
cDNA (to plasminogen activator inhibitor) was detected, possibly
because the transcription of these other induced genes was depen-
dent on protein synthesis. Based on the intensity of the differential
signal, 40 of the 200 cDNAs were selected for further analysis by
cross hybridization. Cross hybridization studies were hampered
by the presence of a repetitive sequence in eight of the 40 cDNAs.
The remaining cDNAs arose from seven unique genes which were
studied further by DNA sequencing, Northern blotting and nu-
clear run on analysis [18].
Induction of the nuclear protooncogene c-jun by TNF
One of the TNF induced differentially hybridizing cDNAs was
found to encode AP-l/c-jun on sequence analysis [17]. The AP-l/
c-jun product is a nuclear protein that forms heterodimenc com-
plexes with the c-fos gene product to stimulate transcription of
genes which contain AP- I/c-jun response elements. AP- I/c-jun
bears similarities to other so-called "immediate early" or "com-
petence" genes such as c-fos and c-myc in that its expression is
suppressed in cells that have been allowed to enter the G0 or
quiescent state. However, mitotic stimulation with serum, purified
growth factors or, in some cases, phorbol esters results in a rapid
transcriptional activation of these genes that is independent of de
novo protein synthesis. Current concepts of the mitogenic re-
sponse hold that the coordinate orchestration of the expression of
these genes is necessary to permit reentry into the G phase of the
cell cycle. Indeed, in fibroblasts where TNF is mitogenic there is
concomitant induction of both c-fos and AP-l/c-jun [17, and
references thereini. In contrast, we found that in endothelial cells
the antiproliferative activity of TNF is accompanied by the
transient transcriptional activation of the AP-l gene. More impor-
tantly, there is no concomitant expression of c-fox or c-inyc
transcripts [17]. Together, these results argue that stimulatory and
inhibitory cytokines induce distinct subsets of immediate early
transcripts which may, in certain cases, contain common mem-
bers such as AP-l/c-jun. The availability of multiple eDNA clones
representing other "immediate early" transcripts in TNF-treated
human umbilical vein endothelial (HUVE) cells will now enable us
to explore more fully the molecular basis of this response and to
document more accurately the overlap between mitogenic and
antimitogenic stimuli postulated here. In any event, our results
argue that the AP-l/c-jun and c-fos genes are controlled by
separate inductive signals. Recent evidence indicating a negative
feedback loop of c-fos protein on the c-fos gene and a positive
feedback loop of AP-lIc-jun protein on its cognate gene supports
this notion.
Cloning of other TNF-induced primary response genes in
HUVE cells
The other six differentially hybridizing cDNAs were further
characterized by both DNA sequencing and Northern blot analy-
sis. This revealed that two of the induced cDNAs were identical to
recently described, cytokine-induced endothelial cell gene prod-
ucts: neutrophil chemotactic factor (NCF), and endothelial leuko-
cyte adhesion molecule-i (ELAM-l). One of the induced cDNAs
was identical to monocyte chemotactic factor (MCF) which was
not a known endothelial cell product, but has been recently
identified and characterized from a human glioma cell line, a
human promyelocytic cell line HL-60, and a human myelomono-
cytic cell line [18 and references thereinj. The remaining three
cDNAs (A20, B61, B94) are not identical to any known gene
product and represent novel TNF induced genes. A short discus-
sion of them follows.
A20. Sequence analysis of a 4.2 kb cDNA revealed that A20
contains a remarkable number of zinc finger motifs (seven)
towards its carboxy terminus [19]. Zinc finger motifs were
originally identified as a DNA binding structure in TFIIIA, an
RNA polymerase III transcription factor [19, and references
therein]. However, since then other zinc fingers have been
described in DNA binding proteins that are involved in RNA
polymerase lI-mediated transcription. They can be classified
into two classes: (i) C2R2 category, which is exemplified by
TFIIIA and consists of proteins containing a highly conserved
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basic structural unit composed of pairs of cysteines and his-
tidines separated by a loop of twelve amino acids. The cysteine
and histidine residues stabilize the domain by tetrahedrally
coordinating a Zn2 ion. (ii) Cx category is exemplified by the
DNA binding domain of steroid and thyroid hormone receptors
[19, and references therein]. This motif uses a variable number
of conserved cysteines for metal chelation. A20, like the steroid
receptors, contains four conserved cysteines C-X4-C-X10-13-C-
X-2-C, where C represents the conserved cysteine and X
indicates intervening amino acid residues. It is important to
note that other than the conserved cysteines, the sequence of
A20 is not identical to members of the human thyroid/steroid
receptor family. Further, since discovery of zinc finger motifs is
considered diagnostic of transcription factors, A20 represents
an excellent candidate for a novel cytokine activatable tran-
scriptional regulatory molecule. In keeping with its proposed
DNA binding function A20 contains a fair enrichment in basic
residues within its finger domains [19].
B6i. The 1.55 kb B61 mRNA is induced within 15 minutes in
human umbilical vein endothelial (HUVE) cells after TNF stimu-
lation. This induction is largely a result of increased transcriptional
rate as assessed by nuclear run-on experiments. B61 message is
similarly induced by IL-i and lipopolysaccharide, but not by
gamma interferon or by endothelial cell growth factor. Addition-
ally, B61 mRNA expression is induced by TNF and IL- 1/3 in both
keratinocytes and IMR-90 fibroblasts in culture. Sequence analy-
sis of cDNA clones encoding B61 reveal that its protein product
has no significant homology to previously described proteins. B61
is primarily a hydrophilic molecule and contains a hydrophobic
N-terminus, which is consistent with the secreted nature of the
protein. The mature form of the predicted protein consists of 187
amino acid residues and has a predicted molecular weight of
22,000 daltons. Immunoprecipitation of metabolically-labeled
HUVE cell preparations indicates that B61 is a 25-kiodalton
secreted protein which is markedly induced by TNF [20, and
references therein].
Since all known TNF induced and secreted proteins derived
from endothelium are paracrine factors such as IL-I, IL-6,
IL-8, MCP-l, M-CSF, G-CSF, GM-CSF, and PDGF [14], we
believe that B61 will fall into this category.
B94. B94 is a 4.2 kb transcript that is induced rapidly, within an
hour of exposure to TNF. Furthermore, in the concomitant
presence of cycloheximide, the B94 transcript is superinduced
which is consistent with it being a primary response gene. Other
proinflammatory stimuli like interleukin-1f3 and lipopolysaccha-
ride are also capable of inducing B94 transcript. Nuclear run-on
studies show that the induction of B94 occurs largely at the
transcriptional level. The induction of B94 protein, as assessed by
immunoprecipitation, parallels induction of the transcript both in
terms of rapidity and magnitude of induction. The protein se-
quence of B94 is not homologous to that of any known pi otein.
However, there are segments that have identity or close similarity
to conserved sequences found in protein kinase catalytic domains,
raising the intriguing possibility that B94 may be a kinase that is
transcriptionally activated.
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